<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Gene expression profiling has recently enabled the reclassification of aggressive non-Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (aNHL) into distinct subgroups </plain></SENT>
<SENT sid="1" pm="."><plain>In Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) aberrant c-Myc activity results from IG-MYC translocations </plain></SENT>
<SENT sid="2" pm="."><plain>However, MYC aberrations are not limited to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLs</z:e> and then have a negative prognostic impact </plain></SENT>
<SENT sid="3" pm="."><plain>In this study, we investigated to which extent aberrant c-Myc activity plays a functional role in other aNHL and whether it is independent from MYC translocations </plain></SENT>
<SENT sid="4" pm="."><plain>Based on a combined microarray analysis of human germinal center (GC) B cells transfected with c-Myc and 220 aNHLs cases, we developed a "c-Myc index." This index measures the extent to which <z:hpo ids='HP_0002665'>lymphomas</z:hpo> express c-Myc responsive genes </plain></SENT>
<SENT sid="5" pm="."><plain>It comprises genes that are affected in a variety of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> compared to <z:mpath ids='MPATH_458'>normal</z:mpath> tissue </plain></SENT>
<SENT sid="6" pm="."><plain>This supports the view that aberrant c-Myc expression in GC B cells triggers a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-like expression pattern </plain></SENT>
<SENT sid="7" pm="."><plain>As expected, the "c-Myc index" is very high in molecular Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (mBL), but more importantly also high within other aNHL </plain></SENT>
<SENT sid="8" pm="."><plain>It constitutes a negative prognostic marker independent of established risk factors and of the presence of a MYC translocation </plain></SENT>
<SENT sid="9" pm="."><plain>Our data provide new insights into the role of c-Myc activity in different <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and raises the question of treatment changes for those patients under risk </plain></SENT>
</text></document>